Interview: Madhusudhan Venkatachari – CEO, Natco Pharma Canada
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Natco Pharma (Canada) Inc. is a Canadian subsidiary of Natco Pharma Limited, India. Natco Pharma Limited is a vertically integrated pharmaceutical company heavily focused in R&D and in manufacturing drug intermediates, API and finished formulations. It has a global network and customer centric approach.
The company exports API’s and Formulations to around 50 countries across the globe. Well known for its impressive portfolio of Oncology, Neurology and CNS drugs, it is bringing to market niche pharmaceuticals.
Natco Pharma has been supplying high quality pharmaceuticals to the Canadian market for more than five years, and, since its formation, has set up a very professional Quality, Regulatory, Warehousing, Marketing, Distribution and Logistics capability to service the Canadian market.
The company is slated to launch some of its already approved generic products and in the process of getting approvals for some very niche and very significant pipeline of pharmaceuticals.
Contact:
Address: 2550 Argentina Road, Suite 116, Mississauga, ON, L5N 5R1 Canada
Tel.: +1 (905) 997 3353
Website: http://natcopharma.ca/
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Luc Boileau, president and CEO of INESSS, the Quebecois National Institute of Excellence in Health and Social Services, the region’s healthcare technology assessment (HTA) body, describes how his organization is…
Kennet Brysting, General Manager of Gilead Sciences Canada, Inc. outlines the strategic significance of the Canadian affiliate to Gilead Sciences globally, including its manufacturing and R&D footprint, the challenge of…
Professor Rémi Quirion, chief scientist of Québec, discusses his mandate, encourages interprovincial collaboration between Ontario and Québec in the life sciences sector and explains the importance of engaging with civil…
Ed Dybka, President of AstraZeneca Canada, highlights the successful ‘return to growth’ journey the affiliate has undergone in the past few years, his thoughts on the need for a renewed…
Lyndal Walker of Ipsen Canada discusses the opportunities present in the Canadian pharma market for a mid-cap innovator like Ipsen, the value of Canada’s research ecosystem, and emerging healthcare trends…
Dr. Gaétan Barrette, Minister of Health and Social Services for Quebec, recaps the ambitious healthcare reforms pertaining to system integration and primary care access he has implemented since assuming position…
Pamela C. Fralick, President of Innovative Medicines Canada (IMC), the innovative pharma association in Canada, looks back on her first half year in position, the challenges of navigating Canada’s complex…
Therapure President and CEO, Nick Green, speaks about the environment for contract development and manufacturing in Canada and the integrated services that Therapure can offer its global customers as a…
Canada operates a single-payer healthcare system in which the majority of services are provided by private entities, which are paid for at the provincial level. The Canada Health Act…
The CEO of DelMar Pharmaceuticals discusses British Columbia’s competitive strengths in the biotechnology space, and demonstrates how his company’s therapy for glioblastoma will change the way in which a number…
John Soloninka, President & CEO of HTX, talks about his vast experience in the pharmaceutical and healthcare sector, why he feels there is much room for growth in Canada still,…
Pierre Montanaro, President and CEO of Pharmetics, discusses the history of his company’s work in the private label business and future plans to expand into a wider variety of areas…
See our Cookie Privacy Policy Here
